Cargando…

The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram

BACKGROUND: To elucidate the optimal number of prostate biopsy cores using a nomogram allocating 6–12 biopsy cores, the number generally used in daily practice, based on age and prostate volume (PV). METHODS: We enrolled 936 patients who received an initial prostate biopsy from April 2006 to January...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Nobumichi, Shimada, Keiji, Nakagawa, Yoshinori, Hirao, Shuya, Watanabe, Shuji, Miyake, Makito, Anai, Satoshi, Hirayama, Akihide, Konishi, Noboru, Fujimoto, Kiyohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652389/
https://www.ncbi.nlm.nih.gov/pubmed/26581414
http://dx.doi.org/10.1186/s13104-015-1668-9
_version_ 1782401743911387136
author Tanaka, Nobumichi
Shimada, Keiji
Nakagawa, Yoshinori
Hirao, Shuya
Watanabe, Shuji
Miyake, Makito
Anai, Satoshi
Hirayama, Akihide
Konishi, Noboru
Fujimoto, Kiyohide
author_facet Tanaka, Nobumichi
Shimada, Keiji
Nakagawa, Yoshinori
Hirao, Shuya
Watanabe, Shuji
Miyake, Makito
Anai, Satoshi
Hirayama, Akihide
Konishi, Noboru
Fujimoto, Kiyohide
author_sort Tanaka, Nobumichi
collection PubMed
description BACKGROUND: To elucidate the optimal number of prostate biopsy cores using a nomogram allocating 6–12 biopsy cores, the number generally used in daily practice, based on age and prostate volume (PV). METHODS: We enrolled 936 patients who received an initial prostate biopsy from April 2006 to January 2009. A number of 6–12 biopsy cores was allocated based on age and PV Nara Urological Research and Treatment Group (NURTG) nomogram. To elucidate the predictive parameters of cancer detection in patients with a prostate specific antigen (PSA) value in the gray zone, univariate and multivariate logistic regression analysis were carried out. RESULTS: The total cancer detection rate and the cancer detection rate in the PSA gray zone (4.1–10.0 ng/mL) were 48.0 and 37.6 %, respectively. The cancer detection rates in the gray zone stratified by patient age of ≤59, 60–64, 65–69, 70–74, 75–79, and ≥80 years were 28.4, 35.0, 26.9, 37.9, 45.7, and 54.8 %, respectively. The significant predictive parameters of cancer detection in the gray zone were age, volume biopsy ratio (VBR: PV divided by number of biopsy cores), PSA density (PSAD), digital rectal examination findings, and transrectal ultrasound findings in univariate analyses. Finally, age, VBR, and PSAD were independent parameters to predict cancer detection in the gray zone. The adverse event profile was acceptable. CONCLUSIONS: Our present study revealed that the cancer detection rate using the NURTG nomogram allocating 6–12 biopsy cores, the number generally used in daily practice, based on age and PV, could provide similar efficacy as previous studies involving more biopsy cores. In older patients the number of biopsy cores could be reduced.
format Online
Article
Text
id pubmed-4652389
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46523892015-11-20 The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram Tanaka, Nobumichi Shimada, Keiji Nakagawa, Yoshinori Hirao, Shuya Watanabe, Shuji Miyake, Makito Anai, Satoshi Hirayama, Akihide Konishi, Noboru Fujimoto, Kiyohide BMC Res Notes Research Article BACKGROUND: To elucidate the optimal number of prostate biopsy cores using a nomogram allocating 6–12 biopsy cores, the number generally used in daily practice, based on age and prostate volume (PV). METHODS: We enrolled 936 patients who received an initial prostate biopsy from April 2006 to January 2009. A number of 6–12 biopsy cores was allocated based on age and PV Nara Urological Research and Treatment Group (NURTG) nomogram. To elucidate the predictive parameters of cancer detection in patients with a prostate specific antigen (PSA) value in the gray zone, univariate and multivariate logistic regression analysis were carried out. RESULTS: The total cancer detection rate and the cancer detection rate in the PSA gray zone (4.1–10.0 ng/mL) were 48.0 and 37.6 %, respectively. The cancer detection rates in the gray zone stratified by patient age of ≤59, 60–64, 65–69, 70–74, 75–79, and ≥80 years were 28.4, 35.0, 26.9, 37.9, 45.7, and 54.8 %, respectively. The significant predictive parameters of cancer detection in the gray zone were age, volume biopsy ratio (VBR: PV divided by number of biopsy cores), PSA density (PSAD), digital rectal examination findings, and transrectal ultrasound findings in univariate analyses. Finally, age, VBR, and PSAD were independent parameters to predict cancer detection in the gray zone. The adverse event profile was acceptable. CONCLUSIONS: Our present study revealed that the cancer detection rate using the NURTG nomogram allocating 6–12 biopsy cores, the number generally used in daily practice, based on age and PV, could provide similar efficacy as previous studies involving more biopsy cores. In older patients the number of biopsy cores could be reduced. BioMed Central 2015-11-18 /pmc/articles/PMC4652389/ /pubmed/26581414 http://dx.doi.org/10.1186/s13104-015-1668-9 Text en © Tanaka et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Tanaka, Nobumichi
Shimada, Keiji
Nakagawa, Yoshinori
Hirao, Shuya
Watanabe, Shuji
Miyake, Makito
Anai, Satoshi
Hirayama, Akihide
Konishi, Noboru
Fujimoto, Kiyohide
The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram
title The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram
title_full The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram
title_fullStr The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram
title_full_unstemmed The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram
title_short The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram
title_sort optimal number of initial prostate biopsy cores in daily practice: a prospective study using the nara urological research and treatment group nomogram
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652389/
https://www.ncbi.nlm.nih.gov/pubmed/26581414
http://dx.doi.org/10.1186/s13104-015-1668-9
work_keys_str_mv AT tanakanobumichi theoptimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT shimadakeiji theoptimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT nakagawayoshinori theoptimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT hiraoshuya theoptimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT watanabeshuji theoptimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT miyakemakito theoptimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT anaisatoshi theoptimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT hirayamaakihide theoptimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT konishinoboru theoptimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT fujimotokiyohide theoptimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT tanakanobumichi optimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT shimadakeiji optimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT nakagawayoshinori optimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT hiraoshuya optimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT watanabeshuji optimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT miyakemakito optimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT anaisatoshi optimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT hirayamaakihide optimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT konishinoboru optimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram
AT fujimotokiyohide optimalnumberofinitialprostatebiopsycoresindailypracticeaprospectivestudyusingthenaraurologicalresearchandtreatmentgroupnomogram